Shenzhen FRD Science & Technology's (SZSE:300602) Earnings Have Declined Over Three Years, Contributing to Shareholders 20% Loss
Shenzhen FRD Science & Technology's (SZSE:300602) Earnings Have Declined Over Three Years, Contributing to Shareholders 20% Loss
No-one enjoys it when they lose money on a stock. But when the market is down, you're bound to have some losers. While the Shenzhen FRD Science & Technology Co., Ltd. (SZSE:300602) share price is down 20% in the last three years, the total return to shareholders (which includes dividends) was -20%. That's better than the market which declined 25% over the last three years. Unfortunately the share price momentum is still quite negative, with prices down 12% in thirty days. We do note, however, that the broader market is down 6.3% in that period, and this may have weighed on the share price.
沒有人會喜歡股票虧錢。但是當股市下跌時,你肯定會有一些虧損者。雖然深圳市富瑞達科技股份有限公司(SZSE:300602)股價在過去三年中下跌了20%,但股東的總回報(包括分紅)卻是-20%。這比過去三年下跌了25%的市場要好。不幸的是,股價的動能仍然非常消極,在30天內下降了12%。但是我們注意到,在此期間更廣泛的市場下跌了6.3%,這可能對股價產生了壓力。
The recent uptick of 5.5% could be a positive sign of things to come, so let's take a look at historical fundamentals.
最近的5.5%上漲可能是事情將要發生的積極跡象,因此讓我們看一下歷史基本面。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
儘管一些人繼續教授有效市場假說,但已經證明市場是過度反應的動態系統,並且投資者並不總是理性的。通過比較每股收益(EPS)和股價的變化情況,我們可以了解投資者對公司的態度如何隨着時間變化而變化。
Shenzhen FRD Science & Technology saw its EPS decline at a compound rate of 13% per year, over the last three years. In comparison the 7% compound annual share price decline isn't as bad as the EPS drop-off. This suggests that the market retains some optimism around long term earnings stability, despite past EPS declines. With a P/E ratio of 56.33, it's fair to say the market sees a brighter future for the business.
深圳市富瑞達科技每股收益以13%的複合年增長率下降,在過去的三年中股價每年下跌了7%。這表明市場對長期收益穩定性仍然保持一定的樂觀情緒,儘管過去EPS有所下降。有一個PE比率爲56.33,可以說市場看好業務的未來。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下面的圖片中查看每股收益如何隨時間變化(單擊圖表以查看確切的價值)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240702/0-5bb65e52ad549631519a4f9f9f00e002-0-28a6fccae28883ad4b2bcba737f9af37.png/big)
We know that Shenzhen FRD Science & Technology has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.
我們知道深圳市富瑞達科技的底線最近有所改善,但是它是否會增長營業收入呢?如果您感興趣,可以查看這份顯示共識營收預測的免費報告。
A Different Perspective
不同的觀點
While it's never nice to take a loss, Shenzhen FRD Science & Technology shareholders can take comfort that , including dividends,their trailing twelve month loss of 2.4% wasn't as bad as the market loss of around 16%. Unfortunately, last year's performance may indicate unresolved challenges, given that it's worse than the annualised loss of 1.2% over the last half decade. Whilst Baron Rothschild does tell the investor "buy when there's blood in the streets, even if the blood is your own", buyers would need to examine the data carefully to be comfortable that the business itself is sound. Before forming an opinion on Shenzhen FRD Science & Technology you might want to consider these 3 valuation metrics.
雖然虧損從來都不是好事,但深圳市富瑞達科技的股東可以安慰,因爲,包括分紅在內,其過去12個月的虧損率爲2.4%,不及大約16%的市場虧損率。不幸的是,去年的表現可能表明存在未解決的挑戰,因爲它比過去五年平均虧損率1.2%更糟糕。雖然巴倫·羅斯柴爾德告訴投資者“在街頭有血時買入,即使血是你自己的血”,購買者需要仔細研究數據,以確信業務本身是合適的。在對深圳市富瑞達科技形成看法之前,您可能需要考慮這3個估值指標。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,您可能在其他地方找到一家出色的企業進行投資。因此,請查看我們預計將實現盈利增長的公司的免費列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。